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Abstract
Introduction: Rapid diagnostic tests (RDT) for HIV infection have high sensitivity and specificity, but in the setting of
longstanding antiretroviral therapy (ART), can give false results that can lead to misinterpretation, confusion and inadequate
management. The objective of this study was to evaluate the proportion of falsely negative results of a RDT performed on
oral fluid in HIV-infected children on longstanding ART.
Methods: One hundred and twenty-nine children with known HIV infection and receiving ART were recruited from the HIV
Clinic at the Harare Central Hospital, Zimbabwe. HIV testing was performed on oral fluid and on finger-stick blood.
Results and Discussion: Children included in the study had a median age of 12 years (IQR 10–14) and 67 (51.9%) were
female. Median age at HIV diagnosis was 5 years (IQR 3–6) and the median time on ART was 6.3 years (IQR 4.3–8.1). The oral
fluid test was negative in 11 (8.5%) patients and indeterminate in 2 (1.6%). Finger-stick blood test was negative in 1 patient.
Patients with a negative oral fluid test had a higher CD4 cell count (967 vs. 723 cells/mm3, p = 0.016) and a longer time on
ART (8.5 vs. 6 years, p = 0.016).
Conclusions: This study found that a substantial proportion of false-negative HIV test results in children on longstanding ART
when using an oral fluid test. This could lead to misinterpretation of HIV test results and in the false perception of cure or
delayed diagnosis.
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Introduction
Rapid diagnostic tests (RDT) for HIV infection using whole-
blood specimens have being used globally since 2005 [1].
These RDTs have high sensitivity, are easy to perform,
require little or no infrastructure, and have a relatively
low cost and a rapid turn-around time making them optimal
for low-resource, high HIV burden settings. However, as
with any test, the performance of the test will depend on
its inherent sensitivity and specificity and the prevalence of
the condition being tested for. The problem of false-positive
test results especially in the context of low HIV prevalence
is well recognized. Serial testing with a highly sensitive test
followed by a confirmatory test with high specificity
addresses this issue [2].
Although RDTs have been widely used both in health
facilities and in community-based HIV testing and counsel-
ling approaches, a key barrier remains the reliance of a
client making contact with a provider and receiving the
test result from the provider, who may be known to the
client. In recent years, there has been increasing interest in
promoting self-testing as a strategy to address these
barriers. Self-testing would enable individuals to undergo
HIV testing confidentially and without concern about
unwanted disclosure of their status to others. A recent
meta-analysis of studies including adults at risk for HIV
infection showed that HIV RDTs performed on blood had
sensitivities and specificities exceeding 98–99% [3]. Oral
fluid tests (OFTs) are RDTs that detect salivary HIV antibo-
dies, and have been shown to have comparable perfor-
mance to blood-based RDTs. As with blood-based RDTs, a
positive OFT result can be confirmed by a subsequent
blood-based test. In 2012, the first OFT received approval
by the Food and Drug Administration as a home-use HIV kit
for self-testing. The use of an OFT as a self-testing strategy
has been demonstrated to be highly acceptable and accu-
rate in Africa [4,5].
OFTs are particularly attractive for use in children because
of their non-invasiveness. Studies have demonstrated a slow
but persistent loss of HIV-specific antibodies in highly sup-
pressed HIV-infected children and adolescents that may lead
to false-negative results in blood-based RDTs [6]. HIV anti-
body titres in saliva are lower than antibody titres in blood,
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which may make OFTs more prone to false-negative results
[3]. This appears to be more frequently encountered in the
setting of longstanding ART and in individuals receiving pre-
exposure prophylaxis (PrEP) [7,8]. We recently observed
several cases of false negative HIV tests using OFT among
children and adolescents taking antiretroviral therapy.
Although this has already been described to occur in adults,
there are no studies focusing on the paediatric population
[9]. To further investigate this, we systematically evaluated
the performance of the OFT compared to the blood-based
RDT among perinatally HIV-infected children aged 7–18 years
established on ART.
Methods
The study was conducted in 2016 and was nested within an
ongoing clinical cohort study among perinatally
HIV-infected children on ART. Children with HIV who had
been receiving ART for at least 18 months were recruited
from the HIV Clinic at the Harare Central Hospital,
Zimbabwe. HIV testing was performed using Ora-Quick
ADVANCE HIV I/II™ OFT (OraSure Technologies,
Bethlehem, USA) for oral fluid and concurrently using a
finger-prick whole-blood sample (Alere Determine HIV 1/2,
Alere Technologies, Jena, Germany). Testing was performed
as per the instructions of the manufacturer by trained
nurses. The nurse who performed the test was blinded to
the result of the other test. CD4 count was assessed using
the Alere PIMA CD4 analyser, and viral load was measured
using GeneXpert HIV-1 Viral Load (Cepheid, Sunnyvale, CA).
Demographic details, age at ART initiation and duration of
ART use were collected.
Statistical analysis was performed using STATA version 14
(Stata-Corp, TX, USA). The Mann–Whitney U-test and
Student’s t-test were used to evaluate for differences
between groups for continuous variables. For categorical
variables, the χ2 test was used. Multivariable logistic regres-
sion was used to examine for factors associated with a false
negative OFT. The level of significance was set at α = 0.05.
Ethical approval for the parent study was obtained from
the Medical Research Council of Zimbabwe, the Biomedical
Research and Training Institute Institutional Review Board
and the London School of Hygiene and Tropical Medicine
Ethics Committee. Written informed consent from guar-
dians and assent from participants were obtained. Specific
verbal consent was also obtained to perform OFTs and
finger-prick samples.
Results and discussion
In total 129 participants were enrolled, with median age
12 years (IQR 10–14), and 67 (51.9%) being female
(Table 1). The study participants had been diagnosed with
HIV infection at a median age of 5 years (IQR 3–6) and the
median duration on ART was 6.3 years (IQR 4.3–8.1). At the
time of the OFT, the median CD4 cell count was
747 cells/mm3 (IQR 474–989) and 30 (34.9%) had a viral
load exceeding 1000 copies/ml. The OFT was negative in
11 (8.5%) patients and indeterminate in two (1.6%). Finger-
prick blood tests were negative in one patient (0.8%) who
also had a negative OFT. Patients with a negative OFT had a
higher CD4 cell count (967 vs. 723 cells/mm3, p = 0.016), a
longer time on ART (8.5 vs. 6 years, p = 0.018) and were
more likely to be girls (76.9% vs. 49.1%, p = 0.057).
Furthermore, children with a negative OFT had a median
age at ART initiation of 4.5 years, while those with a
positive test had a median age of 6.2 years although this
was not statistically significant (p = 0.138). Only 5 (3.9%)
children were started on ART within their first year of life.
There was no association between age at ART initiation and
a false-negative OFT result. While this was a pre-defined
variable to be included in multivariable analysis, this was
not done due to a strong collinearity with duration of ART.
Notably, 64% of those with a positive OFT had a viral load
<1000copies/ml compared to 78% of those with a false-
negative OFT result.
This study shows that a substantial proportion of children
and adolescents receiving ART have a false-negative or inde-
terminate HIV test result using an OFT. Significantly more
false-negative results occurred using an OFT compared to a
whole-blood-based HIV RDT. While false-negative RDT
results, can be due to technical issues such as inappropriate
performance and self-interpretation of the test, this was not
the case in this study where HIV testing was performed by
Table 1. Characteristics of patients by oral mucosal test result
Total
n = 129 Positive OMT n = 116 Negative or indeterminate OMT n = 13 p-Value
Female, n (%) 67 (51.9) 57 (49.1) 10 (76.9) 0.057
Age at study visit (years), median (IQR) 12 (10–14) 12 (10–14) 12 (11–15) 0.464
Age at HIV diagnosis (years), median (IQR) 5 (3–6) 5 (3–6) 4 (1–7) 0.415
Age at ART initiation (years), median (IQR) 6 (4–8.3) 6.2 (4.1–8.4) 4.5 (1.4–7) 0.138
Time on ART (years), median (IQR) 6.3 (4.3–8.1) 6 (4.1–8) 8.5 (7.2–9.4) 0.018
Current CD4 cell count (cells/µl), median (IQR) 747 (474–989) 723 (457–928) 967 (754–1414) 0.016
*Viral load <1000 copies/ml, n (%) 56 (65.1) 49 (63.6) 7 (77.8) 0.400
*data available for 86 participants only. Of the total number of individuals where the viral load measurement was available, 9 had a negative
or indeterminate OMT and 77 had a positive OMT.
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trained nurses certified to provide HIV testing, and the oral
fluid and the blood-based RDTs were performed concur-
rently [10].
False-negative test results on blood-based antibody tests
have been shown to occur very early or very late in the
course of disease [11], as well as a slow loss of HIV-specific
antibodies among children with longstanding ART [6]. In
addition, false-negative HIV tests have been reported in
infants started on ART therapy soon after birth who were
HIV DNA PCR-positive [12,13]. This may be explained by the
decreased antigen presentation due to longstanding sup-
pressed viral replication. Similarly, it could also be asso-
ciated with the time between infection and ART initiation.
For example, false-negative tests have been reported in
children with perinatal HIV infection who were started on
ART within the first months of life [14]. Furthermore, PrEP
was shown to be associated with a delayed time to devel-
opment of a reactive OFT when compared to placebo [15].
Since there appears to be an association between the early
initiation of ART and test performance, false-negative OFTs
while on treatment may become more common in both
paediatric and adult populations due to the global move
towards immediate treatment initiation following a positive
HIV test. This underscores the importance of patient coun-
selling to understand the implications of HIV infection and
therapeutic goals for ART.
The sensitivity of the oral fluid-RDTs is high, reaching up to
100% (95%CI 97.9–100) when used for HIV screening of
individuals who have never received ART [16]. However, this
does drop among those who are taking ART. A longer dura-
tion of ART use and a high CD4 cell count were independently
associated with a false-negative OFT in our study (Table 2).
Those with a suppressed viral load appeared more likely to
have a false-negative test, although we were not able to
formally test for this association due to the large proportion
of participants on whom viral load data was unavailable.
Taken together, these findings imply that in this age group,
those who have been on longstanding ART and robust immu-
nological status have too low levels of antibodies to be
detectable by OFTs. Although not statistically significant, an
interesting finding was the higher rates of false-negative OFT
test in females, although there was no association of gender
with false-negative tests.
Oral fluid-based RDTs are an attractive test for self-
testing, as it is convenient to use and ensures anonymity
and confidentiality [17]. In some settings, oral fluid-based
tests are available over-the-counter or through online
purchase In addition, the World Health Organization
is encouraging countries to initiate pilot projects to
implement and evaluate effective strategies for HIV self-
testing as a means of achieving universal coverage of HIV
testing [18]. Belief in faith healing or in the use of alter-
native treatments to cure HIV has been commonly
reported in some populations with individuals living with
HIV undergoing retesting to check for cure [19]. In a study in
Tanzania, 44% of participants to a study believed that certain
alternative treatments can cure HIV [20], and in another
study seeking cure at a faith healer was associated with a
significant decrease in treatment adherence [21]. In the
absence of adequate counselling and patient education, a
false-negative test result may lead to a wrong perception of
cure, leading to ART interruption and exit from HIV care [12].
Additionally, with the scale up of PrEP, there is a possible risk
of delayed HIV diagnosis given the longer time required for
OFT to become positive in individuals taking PrEP.
Furthermore, false-negative tests might cause the underesti-
mation of HIV prevalence in surveys if participants under-
report their HIV status. In a recent survey we conducted
among 7–18 year olds, 12.9% of HIV-infected participants
had a false-negative oral-fluid-based HIV test result (manu-
script in preparation).
The limitation of this study is that it included a relatively
small number of children from one centre and the lack of a
longitudinal assessment. In addition, viral load tests were
missing in a third of patients and therefore the association
between viral load suppression and false-negative OFT test
results could not be reliably examined.
In conclusion, 10% of older children and adolescents with
HIV infection who were on longstanding ART had falsely
negative or indeterminate HIV test results when using the
oral fluid HIV test. Awareness of the possibility of false-
negative results among healthcare providers and patients
taking ART as well as among clients accessing PREP is
critical, as self-testing is scaled up. Clear counselling and
appropriate messaging are important to avoid misinterpre-
tation of HIV test results, which could result in the false
perception of cure or delayed diagnosis of HIV infection
among those accessing PREP. Additionally, improving sensi-
tivity of OFTs, counselling to prevent their use in individuals
already diagnosed with HIV infection and new testing stra-
tegies are of paramount importance to avoid confusion and
misunderstanding.
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